All News
#BestACR20Tweets
RT @RichardPAConway : Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/TR9IS9hUgu
Dr. John Cush RheumNow ( View Tweet)
Check on Pneumococcal Vaccination: Dr. Janet Pope ( @Janetbirdope) #ACR20
https://t.co/D9EQ3Tl2Ot https://t.co/Zn8IVorCcs
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @RADoctor: Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
Dr. John Cush RheumNow ( View Tweet)
Vaccination with Shingrix: Does it work for patients on JAKi? #ACR20
https://t.co/PLWn3SshcI https://t.co/APBcfP1zlH
Links:
Dr. John Cush RheumNow ( View Tweet)
Vaccination with Shingrix: Does it work for patients on JAKi?
Dr. Jeffrey Curtis examines abstracts #1997 and #0452 presented at the ACR 2020 annual meeting.
Read Article
Flu and Tofacitinib
Dr. Kathryn Dao reviews abstract L04 - Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program - at the 2020 ACR annual meeting.
Read Article
Great read! "The Vaccine Review Process and Why You Should Know It" by Dr. Rachel Tate ( @uptoTate)
https://t.co/l39qH3LuXm https://t.co/PR1AaQCD7V
Links:
Dr. John Cush RheumNow ( View Tweet)
The Vaccine Review Process and why you should know it
There is much controversy regarding vaccine safety and efficacy in the United States. Prior to COVID19, there were populations who lacked confidence in vaccination for any number of reasons. Dr.
Read Article
COVID and Rheumatic Disease Patients: Dr. Kevin Winthrop
Portland-based Dr. Kevin Winthrop from OHSU discusses Saturday ACR 2020 posters #0623 and #0629 related to COVID-19 and rheumatic disease patients.
Read Article
ACR20 - Day 4 Report
Here are my highlights from day four, Monday, of the ACR 2020 Convergence.
Vaccine Immunogenicity with Tofacitinib
Read Article
New podcast out now on our site #ACR20
Mid-Meeting Recap: Psoriatic Arthritis, Gout Patient Outcomes on Low-Dose Steroids, Giant Cell Arteritis Panel Vaccination w/ Shingrix: Does it work for patients on JAKi? Is it safe?
https://t.co/roc1Qjec5R https://t.co/gSkkj2Kl0m
Links:
Dr. John Cush RheumNow ( View Tweet)
📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future
👉close surveillance ➡️ early detection of iRAEs➡️ early treatment➡️ reversibility or ⬇️severity
#ACRAmbassador https://t.co/AM2mfYmAtI
Elizabeth Graef SituationRheum ( View Tweet)
"The goal of a vaccine is not just to protect a (vaccinated) individual, but to end the pandemic." Dr. Dan Barouch #ACR20 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
Jeffrey Curtis RADoctor ( View Tweet)
Just watched David Beck’s talk on somatic mutations in VEXAS. Genotyping to link phenotypically diverse disease. Such an exciting strategy to identify additional unknown diseases!!! #ACR https://t.co/gU9HEZyjRP
Adam J Brown AdamJBrownMD ( View Tweet)
Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis patients taking #JAKinhibitors
- Most RA pts on JAKi have sufficient antibody response to HZ vaccine
- Acceptable safety profile
Abs#1997 #ACR20 @RheumNow
https://t.co/8HWAIwOATD
Mrinalini Dey DrMiniDey ( View Tweet)
Just a reminder:
inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced.
@LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/qdEpNpzdNs
David Liew drdavidliew ( View Tweet)
Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0
Richard Conway RichardPAConway ( View Tweet)
Dr Winthrop reports on rates of influenza in RA in tofactinib clinical programme over 14-15 seasons. No significant differences in rates between tofa, ADA, MTX, and placebo. @rheumnow #ACR20 Abstr#L04 https://t.co/8RrG0I2Zwm
Richard Conway RichardPAConway ( View Tweet)
Retrosp study in France compared MRIs of 96 pts w/ SpA (65% w/ IBP) vs 104 w/o (25% w/ IBP):
- 65% of pts w/ SpA had bone marrow edema (BME) mainly in the iliac quad of intermed middle segment
- 20% w/o SpA had BME mainly in antero-middle quad. #Abst1535 #ACR2020 @RheumNow https://t.co/1ptGGUbUS4
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)